Uncategorized
VIDEO: CEO shares new data on Dextenza
LAS VEGAS — At the Ophthalmology Innovation Summit, Amar Sawhney, PhD, president and CEO of Ocular Therapeutix, discusses the latest clinical trial data on Dextenza (sustained-release dexamethasone 0.4 mg) for ocular itching associated with allergic conjunctivitis.